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The Korean Society of Nephrology (KSN) launched the ofﬁcial end-stage renal disease
(ESRD) patient registry in 1985, and an Internet online registry program was opened in
2001 and revised in 2013. The ESRD Registry Committee of KSN has collected data on
dialysis therapy in Korea through the online registry program in the KSN Internet
website. The status of renal replacement therapy in Korea at the end of 2012 is described
in the following. The total number of ESRD patients was 70,211 at the end of 2012, which
included 48,531 hemodialysis (HD) patients, 7,552 peritoneal dialysis (PD) patients, and
14,128 functioning kidney transplant (KT) patients. The prevalence of ESRD was 1,353.3
patients per million population (PMP), and the distribution of renal replacement therapy
among ESRD patients was as follows: HD, 69.1%; PD, 10.8%; and KT, 20.2%. The number of
new ESRD patients in 2012 was 11,742 (HD, 8,811; PD, 923; and KT, 1,738; the incidence
rate was 221.1 PMP). The primary causes of ESRD were diabetic nephropathy (50.6%),
hypertensive nephrosclerosis (18.5%), and chronic glomerulonephritis (18.1%). The mean
urea reduction ratio was 67.9% in male and 74.1% in female HD patients. The mean Kt/V
was 1.382 in male and 1.652 in female HD patients. The 5-year survival rates of male and
female dialysis patients were 70.6% and 73.5%, respectively.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The Korean Society of Nephrology (KSN) has the largest
continuous end-stage renal disease (ESRD) patient registry,
established in 1985, in which all KSN members are participat-
ing voluntarily: the “Insan Prof. Min Memorial ESRD Patient
Registry.”
The objectives and importance of the patient registry and
statistical evaluation of ESRD can be summarized as follows: (1) to
estimate the numbers and distributions of target therapy patientsn Society of Nephrology. Publi
c-nd/4.0/).
e 33rd autumn meeting of Kor
mittee of Korean Society of N
rsity, Inchon, Korea), Jong Soo
olic University of Korea, Seoul
al Medicine, Saint Vincent’s H
).by a dialysis specialist group (KSN); (2) to know the characteristics
of ESRD and dialysis therapy, and its complications or results
based on scientiﬁc evidence; and (3) to improve the quality of
dialysis therapy, and provide information on socioeconomic health
administration and the future health plan.
In 2013, because vascular access and dialysis quality became
more important, KSN ESRD Committee has revised the online
registry program. Newly included items were vascular access,
dialysate components, calcium and phosphorous control, and
rehabilitation status [1].shed by Elsevier. This is an open access article under the CC BY-NC-ND
ean Society of Nephrology, October 2013. Data from the Insan Memorial
ephrology: Dong Chan Jin, Nam Ho Kim (Chonnam National University,
Lee (Ulsan University, Ulsan, Korea), Sung Ro Yoon (Kunyang University,
, Korea).
ospital, The Catholic University of Korea, 93 Jungbu-daero, Paldal-gu,
Kidney Res Clin Pract 33 (2014) 9–1810Data collection method
The ESRD Registry Committee of KSN has collected data
on dialysis centers and patients through an online registry
program on the KSN Internet website (http://www.ksn.or.0 
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Figure 1. Prevalence and incidence of end-stage renal replacement thera
the end of each year (A); point prevalence of renal replacement therapy (B
major causes of end-stage renal disease (D). CGN, chronic glomeruloneph
nephrosclerosis; KT, kidney transplantation; PD, peritoneal dialysis; PMP, pa
Table 1. Causes of end-stage renal diseases in new patients
Causes
1992 1994 1996 1998 2000
Chronic glomerulonephritis 25.3 25.5 21.6 17.9 14.0
Not histologically conﬁrmed 19.7 20.4 16.7 13.6 10.6
Histologically conﬁrmed 5.6 5.0 4.9 4.3 3.4
Diabetic nephropathy 19.5 26.1 30.8 38.9 40.7
Hypertensive nephrosclerosis 15.4 20.8 18.3 17.8 16.6
Cystic kidney disease 2.1 2.2 1.8 1.7 2.2
Renal tuberculosis 1.1 1.5 1.2 0.5 0.4
Pyelo/interstitial nephritis 1.3 1.1 0.7 1.0 0.8
Drugs or nephrotoxic agents 1.3 0.1 0.6 0.3 0.3
Lupus nephritis 0.8 0.7 1.0 0.5 0.9
Gouty nephropathy 0.7 0.7 0.6 0.5 0.7
Hereditary nephropathy 0.3 0.7 0.4 0.2 0.1
Kidney tumor 0.1 0.1 0.2 0.2 0.2
Other 4.1 2.7 2.8 3.9 3.0
Uncertain 28.6 17.8 15.9 16.6 20.2kr) launched in 2001 and revised the program in 2013. The
program also has a graphic evaluation function of dialysis
adequacy [Kt/V and normalized protein catabolic rate
(nPCR)] and a peritoneal equilibrium test. For ensuring the
security of patients’ personal information, the program33 50 74 85 
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%
2002 2004 2006 2008 2009 2010 2011 2012
13.9 12.5 13.0 12.1 11.1 11.3 10.4 8.1
10.0 8.6 9.0 8.2 7.5 7.7 6.9 4.5
3.9 3.9 3.9 3.8 3.6 3.6 3.5 3.6
40.7 43.4 42.3 41.9 45.4 45.2 47.1 50.6
16.0 16.2 16.9 18.7 18.3 19.2 19.6 18.5
1.6 1.4 1.7 1.7 1.8 1.7 1.6 1.8
0.5 0.3 0.3 0.2 0.2 0.2 0.2 0.0
0.6 0.6 0.6 0.5 0.5 0.4 0.4 0.5
0.4 0.2 0.3 0.3 0.3 0.3 0.5 0.4
0.8 0.6 0.6 0.6 0.6 0.5 0.5 0.6
0.4 0.5 0.3 0.3 0.3 0.4 0.2 0.3
0.2 0.3 0.3 0.3 0.2 0.2 0.2 0.5
0.3 0.3 0.2 0.2 0.2 0.2 0.3 0.3
5.6 5.9 6.0 5.8 5.2 5.1 5.0 6.8
19.0 17.8 17.5 17.6 16.0 15.3 14.3 11.4
Jin and Han / Renal replacement therapy in Korea 2012 11was accessible only to designated dialysis staff with a
hospital code and password. Information on nonresponding
dialysis centers was collected through questionnaires sent
by mail.Data on dialysis therapy in Korea
Prevalence and incidence of ESRD in Korea
At the end of 2012, in Korea, the number of overall ESRD
patients was 70,211, and that of ESRD patients under
maintenance hemodialysis (HD), peritoneal dialysis (PD), and
with functioning transplanted kidney were 48,531, 7,552, and53 60 59 57 54 53 56 57 57 59
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Figure 2. Renal replacement therapy modalities. Proportion of renal repl
numbers of hemodialysis centers and hemodialysis machines (B), and hemod
percent distribution of hemodialysis patients according to dialysis center cla
HD, hemodialysis; KT, kidney transplantation; PD, peritoneal dialysis.14,128, respectively. The prevalence per million population
(PMP) was 935.4 for HD, 145.6 for PD, 272.3 for kidney
transplantation (KT), and 1,353.3 for overall ESRD (Figs. 1A,
1B). These ESRD prevalence rates are slightly higher than those
in most European countries, but about 60% of those in the
United States and about 40% of those in Japan, according to the
international comparison data of the annual United States
renal data report [2–4]. The annual increase in the prevalence
rate was about 10% during 2000–2012.
The number of new patients undergoing renal replacement
therapy in 2012 was 11,472 (221.1 PMP). The number of new
ESRD patients with HD, PD, and KT were 8,811 (169.8 PMP),
923 (17.8 PMP), and 1,738 (33.5 PMP), respectively (Fig. 1C).
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Kidney Res Clin Pract 33 (2014) 9–1812since 2007, whereas those with HD and KT have been
increasing continuously; this is consistent with the trend
observed in the United States [2].
The most common causes of ESRD in new patients were
diabetic nephropathy, hypertensive nephrosclerosis, and
chronic glomerulonephritis (50.6%, 18.5%, and 8.1%, respec-
tively; Table 1). Among these three underlying diseases, the
incidence of diabetic nephropathy increased rapidly during
1990–2000 (Fig. 1D). The proportion of diabetic nephropathy
in ESRD patients in Korea was one of the highest in the world,
which was similar to some Asian countries and the United
States [2].
Renal replacement therapy modalities
Approximately 77% of new ESRD patients in 2012 started HD
as their initial renal replacement therapy, whereas approxi-
mately 8% started PD. The prevalence rates of HD, PD, and KT
were 69%, 11%, and 20%, respectively (Fig. 2A).
The numbers of HD centers and HD machines have also
been increasing rapidly in Korea. At the end of 2012, Korea had
691 HD centers and 18,901 HD machines (Fig. 2B). The ratio of
machines per center was about 27, and that of patients per
machine was 2.6 (Fig. 2C). Approximately one-third of main-
tenance HD patients were admitted to university hospitals in
the late 1990s, but currently, about 46% of HD patients are
treated in private dialysis clinics (Fig. 2D).
An analysis of the distribution of ESRD patients according to
the zones in Korea showed that approximately 50% of HD
patients and more than 50% of PD patients were located in the
capital area (Fig. 2E).
Dialysis patient demographics
The gender ratio of dialysis patients was 57.5% male and
42.5% female in HD therapy and 56.1% male and 43.9% female
in PD therapy (Fig. 3A).
The ABO blood type distribution of dialysis patients was
type A, 34%; type B, 27%; type AB, 12%; type O, 27%, which was
not different from the general population. Hepatitis B virus
antigen was positive in 6% of dialysis patients and hepatitis C
virus antibody in 4% (Fig. 3B).
The mean age of dialysis patients was 59.2714.1 years. The
age distribution of dialysis patients showed two peaks, one at the
age of 50 years and the other at the age of 65 years (Fig. 3C),
indicating that at least two or more different disease groups are
present among ESRD patients. The age distribution according to
year since 1986 showed that the peak age has been shifting to
older age and the current peak age is in the 60s (Fig. 3D). The
percentage of dialysis patients aged more than 65 years increased
to up to 37.5% of overall dialysis patients in 2012.
The age distribution according to underlying diseases showed
that the peak age of chronic glomerulonephritis was 53.7 years
and that of diabetic nephropathy was 61.8 years (Fig. 3E).
About 45% of HD patients and 44% of PD patients had been
undergoing dialysis for more than 5 years; these percentages
had increased from 30% and 14%, respectively, in 2001 (Fig. 3F).
Approximately 53% of nondiabetic HD patients had been
undergoing dialysis for more than 5 years, whereas only 35% of
diabetic HD patients had been undergoing dialysis for the same
period. Similarly, approximately 49% of nondiabetic PD patients
and 34% of diabetic PD patients had been undergoing dialysis for
more than 5 years (Fig. 3G).The mean body mass index was 22.173.4 kg/m2 in HD
patients and 24.273.7 kg/m2 in PD patients; this showed a steady
increase in both HD and PD groups. In HD patients, the mean body
mass index was 22.673.5 kg/m2 in diabetic patients and
21.773.2 kg/m2 in nondiabetic patients (Fig. 3H).
The mean blood pressures were similar between HD and PD
patients (99.7712.5 mmHg and 98.0712.8 mmHg, respectively;
Fig. 3I), but the pulse pressure was much higher in HD patients
than in PD patients (64.2 mmHg vs. 52.2 mmHg, Fig. 3J). Although
the blood pressure of dialysis patients is decreasing, the pulse
pressure of HD patients is increasing; this might be associated
with the risk of cardiovascular morbidity.
Characteristics of HD, PD, and erythropoietin therapy
HD frequency, dialyzer, and dialysate
Most HD patients received dialysis three times per week
(Fig. 4A) since 2000 (91.3% in 2012). Hemodiaﬁltration therapy
was performed in 11% of HD patients, but 53% of HD patients
received dialysis with a dialyzer having a surface area of less
than 1.5 m2 (Fig. 4B). Mostly bicarbonate and standard calcium
(3.0 mEq/L) with glucose dialysate were used (Fig. 4C).Vascular access for HD
Of the HD patients, 79% had autologous arteriovenous
ﬁstula, of which 50% was in the left forearm, and 14% had
graft ﬁstula (Fig. 4D).PD catheter and dialysate dose
Of the PD patients, 48% had swan neck PD catheters and 23%
had straight PD catheters. The PD catheter was inserted surgically
in 62% of PD patients. The break-in period after catheter insertion
was mostly 2–3 weeks, for both surgical and trochar insertions
(Fig. 4E). Automated PD therapy was applied to 24% of PD
patients, and a PD dialysate volume of 10–12 L/day was used in
48% of PD patients (Fig. 4F).Anemia and erythropoietin therapy
In 2012, the mean hemoglobin level of HD patients was
10.471.1 g/dL and that of PD patients was 10.271.3 g/dL
(Fig. 4G). Although, theoretically, PD patients have a lower
prevalence of anemia than HD patients, the recent use of
erythropoietin therapy has increased hemoglobin levels in HD
patients more than in PD patients. This therapeutic result is
shown clearly in Figs. 4G and 4H: Of the HD patients, 46% were
injected with 8,000 or more units of erythropoietin per week,
whereas only 33% of PD patients were injected with this level
of erythropoietin and 19% of PD patients were not injected
with erythropoietin. The signiﬁcant increase in the hemoglo-
bin level of both dialysis patients in 2004 and 2005 was due to
an increase in the reimbursement level of hemoglobin by the
National Health Insurance.Laboratory data and medications
The distribution of patient numbers according to calcium and
phosphorous levels is shown in Fig. 4I; the mean total calcium
and phosphorous levels in HD patients were 8.8870.89 mg/dL
and 5.1471.64 mg/dL, respectively. Serum intact parathyroid
hormone level of dialysis patients has been shown as a nature
logarithmic scale distribution (Fig. 4J).
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Figure 3. Dialysis patient demographics. Gender ratio of HD and PD patients according to year (A); ABO blood type and hepatitis virus of HD and PD
patients (B); age distribution of dialysis patients according to dialysis modalities (C), years (D), and underlying diseases (E); duration of maintenance
HD and PD versus percent of estimated patient number according to year (F); duration of dialysis maintenance in diabetic and nondiabetic patients
(G); distribution of BMI (H) and mean blood pressure (I) in HD and PD patients (blood pressure is higher in HD patients than in PD patients); and
systolic and diastolic blood pressures with pulse pressure in HD and PD patients (J). BMI, body mass index; BP, blood pressure; DM, diabetic patients;
HD, hemodialysis; HTN, hypertensive nephrosclerosis; GN, glomerulonephritis; MBP, mean blood pressure; PD, peritoneal dialysis.
Jin and Han / Renal replacement therapy in Korea 2012 13
Kidney Res Clin Pract 33 (2014) 9–1814
Figure 4. (continued)
Figure 4. Characteristics of HD, PD, and erythropoietin therapy. Frequency of hemodialysis per week (A); percent of HDF-applied patients and
dialyzer membrane surface area (B); hemodialysis dialysate (C); vascular access for HD (D); PD catheter type and PD catheter insertion methods (E);
Distribution of peritoneal dialysis types and doses (percentage) (F); changes in hemoglobin level in dialysis patients, HD versus PD (note the increase
of hemoglobin in HD patients) (G); percent distribution of erythropoietin doses prescribed for HD and PD patients (H); distribution of patients
numbers according to calcium and phosphorous levels (I); PTH levels of HD and PD patients (x-axis is on nature logarithmic scale) (J); phosphate
binders and PTH control medications (K); distribution of URR in hemodialysis patients (L); dialysis adequacy parameters (nPCR and spKT/V) in HD
patients (M); dialysis adequacy parameters (spKt/V) in diabetic and nondiabetic HD patients (N); and distribution of patient numbers according to
nPCR and spKt/V in HD patients (O) and according to nPNA and Kt/V in PD patients (P). APD, automated peritoneal dialysis; AVF, arteriovenous ﬁstula;
CAPD, continuous ambulatory peritoneal dialysis; EPO, erythropoietin; Hct, hematocrit; HD, hemodialysis; HDF, hemodiaﬁltration; nPCR, normalized
protein catabolic rate; nPNA, normalized protein nitrogen appearance; PD, peritoneal dialysis; PTH, parathyroid hormone; spKt, single-pool Kt/V;
URR, urea reduction ratio.
HD    
1 yr : 94.7%
3 yr : 82.8%
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PD    
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3 yr : 82.5%
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Figure 5. Rehabilitation, morbidities, causes of death, and survival rates of dialysis patients. Rehabilitation status of HD and PD patients in 2012 (A);
comparison of causes of death in HD versus PD patients in 2001–2012 (B); overall survival of dialysis patients registered since 2001 (C); survival of HD and
PD patients since 2001 (D); and patient survival according to underlying diseases since 2001 (E). DM, diabetic nephropathy; GN, glomerulonephritis; HD,
hemodialysis; HTN, hypertensive nephrosclerosis; Misc, miscellaneous; PD, peritoneal dialysis.
Kidney Res Clin Pract 33 (2014) 9–1816Calcium bicarbonate or acetate was used in 67% HD patients
as a phosphate binder, and 24% of HD patients received
vitamin D therapy (Fig. 4K).
The mean serum albumin, creatinine, cholesterol, uric acid,
and HbA1c levels in HD patients were 3.9 g/dL, 9.68 mg/dL,
144.0 mg/dL, 7.22 mg/dL, and 6.92%, respectively.Dialysis adequacy
The mean urea reduction ratio was 67.9% in male and 74.1%
in female HD patients (Fig. 4L). This gender difference of
dialysis adequacy resulted from the use of similar dialysis
doses in men and women despite a body mass difference
between the genders. The overall mean urea reduction ratio
was 70.577.1%; which showed a steady increase.
The average nPCR and single-pool Kt/V were 0.9870.28 and
1.4970.29, respectively. Similar to the urea reduction ratio, boththese values were higher in women than in men (Fig. 4M).
Single-pool Kt/V was higher in nondiabetic patients than in
diabetic patients, presumably because of the quality of vascular
access for dialysis (Fig. 4N). The recent protein catabolic rate
showed a slight decrease, presumably because of the increase in
the proportion of elderly dialysis patients.
Distribution of patient numbers according to nPCR and single-
pool Kt/V in case of HD patients and that according to nPNA and
PD Kt/V in case of PD patients are shown in Figs. 4O and 4P.Rehabilitation, morbidities, causes of death, and survival rates
of dialysis patients
Rehabilitation
Of the PD patients, 33% had full-time jobs and 24% part-
time jobs, but only 24% of HD patients had full-time jobs in
Table 2. Comorbidities of dialysis patients in 2012
Variables Hemodialysis patients (%) Peritoneal dialysis patients (%)
Cardiac 18.0 14.2
Coronary artery disease 9.3 7.6
Congestive heart failure 4.3 5.0
Pericardial effusion 0.5 0.5
Arrhythmia 3.8 1.1
Vascular 51.2 60.7
Cerebrovascular accident 3.7 4.2
Hypertension 45.9 55.3
Other vascular disease 1.6 1.2
Infection 5.0 8.5
Pneumonia 1.3 1.1
Tuberculosis 0.5 1.1
Peritonitis 0.4 3.1
Herpes zoster 0.3 0.4
Access/exit site infection 0.3 0.6
Other infections 2.2 2.2
Liver disease 7.9 4.6
Hepatitis B 4.6 3.4
Hepatitis C 2.9 0.8
Congestive liver 0.1 0.0
Hemochromatosis 0.0 0.0
Other liver diseases 0.3 0.4
Gastrointestinal 10.8 6.4
Gastric ulcer 2.3 1.0
Duodenal ulcer 0.4 0.3
Constipation 1.7 0.2
Other gastrointestinal diseases 6.3 4.9
Miscellaneous 7.0 5.6
Malnutrition (Alb o 2.5 g/dL) 0.2 0.4
Malignancy 1.4 1.3
Hypertensive retinopathy 0.9 0.6
Uremic dermatitis 0.8 0.5
Uremic neuritis 1.2 0.7
Uremic dementia 0.3 0.2
Uremic ascites/pleural effusion 0.4 0.5
Osteodystrophy 0.6 0.3
COPD and other pulmonary diseases 0.2 0.2
Decubitus ulcer/DM foot 1.0 0.9
Alb, serum albumin; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus.
Jin and Han / Renal replacement therapy in Korea 2012 172012 (Fig. 5A). This means that a higher rehabilitation rate was
achieved in PD patients.Comorbidity
The most common complications (51.2%) in HD patients
were vascular diseases, which included hypertension, cerebro-
vascular accident, and other vascular diseases (Table 2).
Furthermore, 60.7% of PD patients had vascular diseases, and
the infectious complication rate was higher in PD patients
(8.5%) than in HD patients (5.0%).Causes of death
The causes of death in dialysis patients in a descending order
of frequency were cardiac causes, infection, and vascular disease.
The cause of death was unknown or miscellaneous in one-
quarter of dialysis patients (Table 3, Fig. 5B). Some year-to-year
variation was observed because of limitations in death reports.Patient survival
The overall 1- and 5-year survival rates of dialysis patients
were 95% and 72%, respectively (Fig. 5C). These survival rates
were higher than those observed in the United States and Japan
[2,3], but the Korean survival rate was calculated only from the
data of dialysis patients registered since 2001. The Korean ESRDRegistry covers only about two-thirds of all dialysis patients in
Korea because registry enrollment is voluntary.
The 5-year survival rate was higher in HD patients than in
PD patients (72.6% vs. 68.3%; Fig. 5D), and the 5-year
survival rate was higher for chronic glomerulonephritis
patients than for diabetic patients (86.4% vs. 61.4%; Fig. 5E).
Kidney transplantation
In 2012, KT was performed in 1,783 cases, which included
768 deceased donors (Fig. 6). The KT rate was 37 cases per
1,000 dialysis patients, which was below the world average
[2]. However, the waiting number has been increasing
sharply, and 12,463 surviving dialysis patients were enrolled
in the Korean Network of Organ Sharing waiting list at the
end of 2012.Conclusion
The increasing proportion of elderly and diabetic patients in
the Korean population has resulted in a rapid increase in the
number of ESRD patients, which reached 1,353 PMP at the end
of 2012. A high proportion of diabetic ESRD patients (50.6%)
and a decrease in the proportion of PD patients were observed
recently. Among ESRD patients, the proportion of HD has
Table 3. Causes of death (%) in dialysis patients, 1994–2012n
1994–1996 1998 2001 2003 2005 2006 2007 2008 2009 2010 2011 2012
Cardiac 27.4 27.4 26.9 31.7 30.7 33.7 31.7 35.1 29.5 31.1 32.7 33.9
Myocardial infarction 6.4 6.4 7.7 7.4 8 9.1 7.5 9.7 8.0 8.3 6.6 6.8
Cardiac arrest,
uremia associated 13.7 13.7 11.2 11.7 10.4 11.1 10.8 11 8.5 8.7 11.0 11.1
Cardiac arrest, other causes 7.2 7.2 8.1 12.5 12.4 13.5 13.3 14.4 13 14.2 15.0 16.0
Vascular 17.2 17.2 22.7 19.5 17 16.5 17.8 16 15.9 13.3 14.1 13.0
Cerebrovascular accident 14.3 14.3 15.1 14.5 12.3 11.5 13 12.2 11 8.2 8.7 7.9
Pulmonary embolus 0.2 0.2 0.5 0.1 0.6 0.7 0.5 0.1 0.2 0.1 0.2 0.3
Gastrointestinal hemorrhage 1.7 1.7 2.7 3.2 1.7 1.8 2.7 1.9 2.3 2.6 2.2 2.3
Gastrointestinal embolism 0.1 0.1 0.1 0 0.5 0.5 0.1 0.1 0.5 0.4 0.1 0.6
Other vascular diseases 0.9 0.9 4.3 1.6 1.9 2 1.6 1.7 1.9 2.2 3.0 1.9
Infection 13.5 13.5 17.8 20.5 20.1 18.8 20.2 19.5 21.9 22.6 23.1 24.5
Pulmonary infection 2.5 2.5 4.5 3.6 4.5 4.2 4.4 4.4 5.9 7.5 8.4 10.8
Septicemia 6.6 6.6 6.9 9.7 9.6 8.9 11.7 9 10.4 10.7 9.7 8.9
Tuberculosis 0.3 0.3 0.8 0.2 0.3 0.1 0.2 0.1 0.3 0.2 0.1 0.7
Peritonitis 2.1 2.1 1.1 2 1.4 1.1 1.1 2 0.8 1.2 1.0 1.0
Other infections 2 2 4.5 4.9 4.3 4.5 2.9 4 4.5 2.9 4.0 3.0
Liver disease 3.4 3.4 2.6 2.8 2.7 2.6 2.2 1.9 3.1 2.7 2.1 2.8
Liver failure due
to hepatitis B 1.8 1.8 1.6 1.8 1.5 1.4 1.3 1 2.2 1.2 1.0 1.4
Liver failure due
to other cause 1.6 1.6 1 1 1.2 1.1 0.8 0.8 0.9 1.6 1.1 1.3
Social 6.2 6.2 6.3 4.4 5.4 4.2 3.3 3.3 2.5 2.9 3.3 2.2
Patient refused
further treatment 2.9 2.9 2.1 1 1.1 0.6 1.1 0.6 0.5 0.3 0.4 0.6
Suicide 2.5 2.5 3.3 2.3 3.3 3 1.5 1.6 1.3 1.9 1.4 1.4
Therapy ceased
for other reasons 0.8 0.8 0.9 1 1 0.6 0.7 1 0.8 0.7 1.5 0.3
Miscellaneous 32 32 23.7 21.3 24 24.2 24.8 24.3 27.1 27.3 24.7 23.6
Cachexia 2.9 2.9 8.1 6.6 4 3.9 4.4 3.8 3.3 2.8 2.7 2.1
Malignant diseases 2.1 2.1 4.4 3.5 6.4 5.4 5.7 4.6 5.7 5.9 6.0 6.7
Accident 1.2 1.2 0.9 1.1 1.4 1.6 1.2 1 1.3 0.6 1.6 1.4
Uncertain 25.8 25.8 10.3 10.1 12.3 13.2 13.4 14.9 16.8 18 14.5 13.3
n Number of patients: 1994–1996, 981; 1998, 911; 2001, 761; 2003, 894; 2005, 1,256; 2006, 1,248; 2007, 1,531; 2008, 1,563; 2009, 1,727; 2010, 1,802;
2011, 1,828; 2012, 1,745.
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Figure 6. Annual number of KTs in Korea (including data from the
KONOS). Surviving KT waiting patient number at the end of each year.
KONOS, Korean Network for Organ Sharing; KT, kidney transplantation.
Kidney Res Clin Pract 33 (2014) 9–1818increased to 69%, PD decreased to 11%, and KT has remained at
20%. The adequacies of dialysis and anemia therapy have been
improving steadily in Korea.Conﬂicts of interest
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